| 摘要 |
Crystalline eliglustat hydrochloride. The present disclosure also generally relates to a pharmaceutical composition comprising crystalline eliglustat hydrochloride, as well of methods of using crystalline eliglustat hydrochloride in the treatment of Gaucher disease, and methods for obtaining such forms. |
